Business Description
Nova Eye Medical Ltd
ISIN : AU0000094252
Total Employee Number:
301Description
Nova Eye Medical Ltd develops and sells surgical devices for the treatment of glaucoma, a cause of blindness. In addition, the company is involved in the commercialisation of the subthreshold nano-pulse ophthalmic laser, 2RT, for the treatment of retinal disease via the AlphaRET segment. The company's reportable segments are: Glaucoma Surgical Devices and AlphaRET. The majority of its revenue is generated from the Glaucoma Surgical Devices segment, which is involved in the design, manufacture, marketing, and sale of the iTrack, iTrack Advance, and the Molteno3 glaucoma surgical device. These are all single-use surgical devices. Geographically, the company generates maximum revenue from the United States of America, followed by Europe, the Asia Pacific, Other regions, and Australia.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.94 | |||||
Equity-to-Asset | 0.67 | |||||
Debt-to-Equity | 0.18 | |||||
Debt-to-EBITDA | -0.4 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 0.6 | |||||
Beneish M-Score | -2.73 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 8.7 | |||||
3-Year EBITDA Growth Rate | 12.1 | |||||
3-Year EPS without NRI Growth Rate | 9.5 | |||||
3-Year FCF Growth Rate | 26.9 | |||||
3-Year Book Growth Rate | -30.9 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 21.23 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 60.57 | |||||
9-Day RSI | 51.52 | |||||
14-Day RSI | 47.93 | |||||
3-1 Month Momentum % | -8 | |||||
6-1 Month Momentum % | -13.21 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.85 | |||||
Quick Ratio | 1.24 | |||||
Cash Ratio | 0.46 | |||||
Days Inventory | 132.17 | |||||
Days Sales Outstanding | 41.55 | |||||
Days Payable | 96.48 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -24 | |||||
Shareholder Yield % | 1.53 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 70.27 | |||||
Operating Margin % | -28.13 | |||||
Net Margin % | -21.27 | |||||
EBITDA Margin % | -21.08 | |||||
FCF Margin % | -16.1 | |||||
OCF Margin % | -14.73 | |||||
ROE % | -40.43 | |||||
ROA % | -27.81 | |||||
ROIC % | -48 | |||||
3-Year ROIIC % | 34.11 | |||||
ROC (Joel Greenblatt) % | -90.8 | |||||
ROCE % | -46.32 | |||||
Years of Profitability over Past 10-Year | 2 | |||||
Moat Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 17.86 | |||||
PS Ratio | 0.91 | |||||
PB Ratio | 1.97 | |||||
Price-to-Tangible-Book | 3.67 | |||||
EV-to-EBIT | -3.44 | |||||
EV-to-EBITDA | -4.52 | |||||
EV-to-Revenue | 0.95 | |||||
EV-to-Forward-Revenue | 0.78 | |||||
EV-to-FCF | -5.65 | |||||
Price-to-GF-Value | 0.61 | |||||
Price-to-Median-PS-Value | 0.58 | |||||
| Price-to-Net-Current-Asset-Value | 11 | |||||
Earnings Yield (Greenblatt) % | -29.2 | |||||
FCF Yield % | -16.98 | |||||
Forward Rate of Return (Yacktman) % | -24.89 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Nova Eye Medical Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | 33.054 | ||
| EPS (TTM) (A$) | -0.025 | ||
| Beta | 2.1555 | ||
| 3-Year Sharpe Ratio | -0.2 | ||
| 3-Year Sortino Ratio | -0.34 | ||
| Volatility % | 67.55 | ||
| 14-Day RSI | 47.93 | ||
| 14-Day ATR (A$) | 0.006315 | ||
| 20-Day SMA (A$) | 0.11125 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (A$) | 0.1 - 0.205 | ||
| Shares Outstanding (Mil) | 284.87 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nova Eye Medical Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Nova Eye Medical Ltd Stock Events
| Event | Date | Price (A$) | ||
|---|---|---|---|---|
| 0.2:1 Stock Split | 2001-07-10 | 0.61 (+0.00%) | ||
| 0.863632:1 Stock Split | 1995-03-30 | -- | ||
| 0.1:1 Stock Split | 1994-03-04 | -- |
Show
Entries
Nova Eye Medical Ltd Frequently Asked Questions
What is Nova Eye Medical Ltd(ASX:EYE)'s stock price today?
The current price of ASX:EYE is A$0.11. The 52 week high of ASX:EYE is A$0.21 and 52 week low is A$0.10.
When is next earnings date of Nova Eye Medical Ltd(ASX:EYE)?
The next earnings date of Nova Eye Medical Ltd(ASX:EYE) is .
Does Nova Eye Medical Ltd(ASX:EYE) pay dividends? If so, how much?
Nova Eye Medical Ltd(ASX:EYE) does not pay dividend.
Press Release
Articles on Nova Eye Medical Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers